Climb Bio, Inc. develops therapeutics for patients with immune-mediated diseases. News about Climb Bio centers on its clinical-stage monoclonal antibody pipeline, including budoprutug, an anti-CD19 antibody for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia and systemic lupus erythematosus, and CLYM116, an anti-APRIL antibody for IgA nephropathy.
Recurring updates include clinical development progress, formulation data, regulatory actions such as FDA Fast Track Designation for budoprutug in primary membranous nephropathy, R&D presentations, business updates and operating results. Company announcements also cover financing activity, governance changes and investor communications tied to its biotechnology development strategy.
Climb Bio (CLYM) will present clinical data for CLYM116 and budoprutug at ASN Kidney Week, held October 21-25, 2026, in Denver.
Preliminary results from the ongoing Phase 2 PrisMN study of budoprutug in primary membranous nephropathy are scheduled for an oral presentation on October 24. Two posters on October 22 and 23 cover Phase 1 safety, tolerability and drug activity in healthy volunteers for the CLYM116 program. A separate October 23 poster covers a budoprutug case study in minimal change disease. Abstracts are available on the ASN 2026 website.
Climb Bio (CLYM) reported initial Phase 1 data for CLYM116, an anti-APRIL monoclonal antibody, supporting every-12-week dosing for IgA nephropathy. The randomized, double-blind, placebo-controlled SAD/MAD study in 46 healthy volunteers evaluated subcutaneous CLYM116 safety, pharmacokinetics, and pharmacodynamics.
A projected ~29-day half-life was observed at the 320 mg multiple-ascending-dose level, described as threefold longer than sibeprenlimab. A single 320 mg dose drove >90% free APRIL suppression and approximately 60–75% suppression of IgA, Gd-IgA1, and IgM, maintained through 12 weeks. CLYM116 was generally well tolerated, with no serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia reported.
The ongoing Phase 2 NAVIGATE-2 IgA nephropathy trial uses an 800 mg loading dose followed by 400 mg every 8 or 12 weeks, aiming to select a single regimen for a planned 2027 Phase 3 registrational study. A high-concentration 200 mg/mL formulation and pre-filled syringe are ready for registrational use, with an autoinjector in development.
Climb Bio (CLYM)/b) will participate in two upcoming investor healthcare conferences in September 2026 via fireside chats.Management will appear at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9 from 4:30–5:05 p.m. ET, and at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16 from 8:30–9:05 a.m. ET. Live webcasts and 30-day replays will be available through the Investors & Media section of Climb Bio’s website.
Climb Bio (Nasdaq: CLYM) reported second quarter 2026 results and pipeline progress for budoprutug and CLYM116. Cash, cash equivalents and marketable securities were $239.2 million as of June 30, 2026, and a $110 million April 2026 private placement is expected to extend the cash runway into the second half of 2028.
For Q2 2026, Climb Bio reported R&D expenses of $9.7 million and G&A expenses of $5.6 million, leading to a net loss of $13.5 million, or $0.18 per share. For the first six months of 2026, net loss was $27.2 million, or $0.38 per share, with total operating expenses of $30.6 million.
According to Climb Bio, key upcoming milestones include initial Phase 1 data for CLYM116 at a September 3, 2026 R&D Spotlight, planned initiation of a Phase 2 IgA nephropathy trial in Q3 2026, and multiple budoprutug data readouts across pMN, ITP, and SLE in Q4 2026.
Climb Bio (Nasdaq: CLYM) reported initial Phase 1b data for budoprutug, an anti-CD19 antibody, in adults with primary immune thrombocytopenia at EHA 2026.
Among 15 heavily pretreated patients, budoprutug showed an encouraging safety profile, >90% B-cell depletion, and higher platelet counts, supporting continued evaluation.
Climb Bio (Nasdaq: CLYM) reported initial Phase 1 safety data and translational modeling results for CLYM116, an anti-APRIL antibody for IgA nephropathy, at ERA Congress 2026. CLYM116 has been generally well tolerated in healthy volunteers with no serious adverse events or dose-limiting toxicities observed.
A global Phase 1 strategy across Australia and China (≈80 participants, 25–640 mg) supports population PK modeling and dose selection. Mabworks expects to start dosing IgAN patients in the Phase 2 portion of its study in Q3 2026, while Climb Bio plans an R&D Spotlight in late summer to share initial PK/PD and updated safety data.
Climb Bio (Nasdaq: CLYM) will present new data on its CLYM116 and budoprutug programs at the European Renal Association (ERA) Congress 2026 in Glasgow, June 3-6, 2026.
Presentations cover PK/PD modeling and initial Phase 1 safety data for CLYM116 in IgA nephropathy and a Phase 2 trial-in-progress poster for budoprutug in primary membranous nephropathy.
Climb Bio (Nasdaq: CLYM) announced it will present new clinical data from its budoprutug program at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden, held June 11-14, 2026.
The poster will share safety, B-cell depletion and initial platelet data from the low-dose 250 mg cohort at 24 weeks in an ongoing Phase 1b/2a trial in adults with primary immune thrombocytopenia (ITP).
Climb Bio (Nasdaq: CLYM) announced participation in two upcoming investor conferences featuring executive team fireside chats.
Events include the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 11:00–11:30 a.m. ET, and the Jefferies Global Healthcare Conference on June 4, 2:35–3:05 p.m. ET, with live and replay webcasts on its website.
Climb Bio (Nasdaq: CLYM) reported Q1 2026 results and program updates on May 7, 2026. Key operational highlights include robust B-cell depletion from budoprutug subcutaneous Phase 1 data, multiple ongoing budoprutug trials with anticipated readouts across 2026, CLYM116 PK/PD modeling to be presented at ERA 2026, and a completed $110 million private placement.
Financials: cash, cash equivalents, and marketable securities of $146.3 million as of March 31, 2026; R&D expense of $9.4 million; G&A expense of $5.8 million; other income, net of $1.5 million.